Close
Help




JOURNAL

Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders

Predictive Factors Related to the Efficacy of Golimumab in Patients with Rheumatoid Arthritis

Submit a Paper


Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders 2015:8 25-32

Original Research

Published on 19 Feb 2015

DOI: 10.4137/CMAMD.S22155


Further metadata provided in PDF



Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders

Abstract

In order to investigate the predictive factors related to clinical efficacy and radiographic progression at 24 weeks by looking at the serum levels of tumor necrosis factor (TNF)-α and interleukin (IL)-6 including baseline characteristics in patients with rheumatoid arthritis (RA) treated with golimumab, serum concentrations of TNF-α and IL-6 were analyzed every 4 weeks up to 24 weeks in 47 patients treated with golimumab. Baseline levels of the Disease Activity Score 28 C-reactive protein (DAS28-CRP) and Simplified Disease Activity Index (SDAI) scores were also assessed. Radiographic progression using the van der Heijde-modified Sharp (vdH-S) score was assessed in 29 patients. Multiple regression analyses related to the DAS28-CRP score and delta total sharp score at 24 weeks was undertaken using the baseline characteristics of patients and serum concentrations of matrix metalloproteinase (MMP)-3, TNF-α, and IL-6. The DAS28-CRP score and SDAI decreased significantly at 4 weeks up to 24 weeks compared with baseline. Serum levels of TNF-α were not changed significantly up to 24 weeks compared with baseline, but those of IL-6 decreased significantly at 4 weeks up to 8 weeks. Multiple regression analyses showed that disease duration and serum levels of MMP-3 were related significantly to the DAS28-CRP score at 24 weeks. Radiographic progression was related significantly to disease duration with regard to joint space narrowing and bone erosion. However, serum levels of TNF-α and IL-6 were not correlated significantly with the DAS28-CRP score and radiographic progression. These data suggest that decreasing serum levels of IL-6 significantly, MMP-3, and disease duration are predictive factors for RA activity in patients taking golimumab.



Downloads

PDF  (1.29 MB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)

XML

PMC HTML


Sharing


What Your Colleagues Say About Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders
The staff of Libertas Academica have been exceptionally easy to work with.  They continually keep authors updated and are responsive to all requests.  They were also very flexible to work with when I had some challenges from my end as an author.  Article reviews were received very promptly and were constructive and helpful for improving the manuscript.  The online submission system was easy to use and provided clear guidance on what was needed.  I highly ...
Dr Brian Gates (Washington State University College of Pharmacy, Spokane WA, USA)
More Testimonials

Quick Links


New article and journal news notification services
Email Alerts RSS Feeds
Facebook Google+ Twitter
Pinterest Tumblr YouTube